A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma — Stella

Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Study of Temodar With Abexinostat (PCI-24781) for Patients With Recurrent Glioma — Stella

Home/Recurrent High Grade Glioma/

View on ClinicalTrials.gov

Recruiting

Back to Recurrent High Grade Glioma trials

Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.

Trial locations(1 site)

United States

University of Nebraska Medical Center, Omaha, Nebraska

Key details

Phase

Early testing

Sponsor

University of Nebraska

Collaborators

Xynomic Pharmaceuticals, Inc.

Enrollment target

~24 participants

Started

June 2023

Primary completion

July 2027

Age range

19 Years and older

Last updated April 2026

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.